Immunotherapy of murine tumor with syngeneic antitumor serum plus BCG.
Murine tumor suppression was observed on combination therapy with antitumor serum and BCG at a low dose. However, no tumor suppression was observed with a relatively high dose of 400 micrograms BCG. Macrophages from mice given a high dose of BCG showed low cytolytic activity but high phagocytic activity in vitro. In BCG- sensitized mice, BCG was effective on early ascitic tumors. Moreover, combination therapy with antitumor serum and BCG was effective on tumors at an advanced stage. These results suggest that in combination, antiserum and BCG have synergistic therapeutic effects on tumors of BCG-sensitized and nonsensitized hosts.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D003602:Cytotoxicity, Immunologic; D007114:Immunization; D007167:Immunotherapy; D066298:In Vitro Techniques; D008264:Macrophages / Q000276:immunology; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D010587:Phagocytosis
D000912:Antibodies, Neoplasm; D001500:BCG Vaccine